Income statement, balance sheet and cash flow statement for the last 3 fiscal years, taken from the XBRL data Camp4 Therapeutics Corp files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2024
FY2024
FY2025
Revenue
0.35
0.65
3.5
Research and development
40.6
38.8
38.2
General and administrative
11.6
14.9
17.4
Operating expenses
52.2
53.7
56.1
Operating income
-51.9
-53.1
-52.6
Interest income
2.81
1.33
2.17
Other non-operating income
2.59
1.3
-27.8
Income tax
0
0
0
Net income
-49.3
-51.8
-80.4
EBITDA
-50.2
-51.4
-50.9
EPS, basic
-124.80
-11.04
-2.65
EPS, diluted
-124.80
-11.04
-2.65
Shares, basic (weighted)
0.39
4.69
30.4
Shares, diluted (weighted)
0.39
4.69
30.4
Dividend per share
0.00
0.00
Balance sheet
FY2024
FY2024
FY2025
Cash and equivalents
38.4
64
110
Other current assets
0.25
0.21
0.34
Total current assets
40
66.4
114
Property, plant and equipment
4.8
3.86
2.34
Lease right-of-use assets
7.76
6.02
0.4
Other non-current assets
0.43
0.08
Total assets
54.9
78.3
118
Accounts payable
1.04
1.21
0.18
Accrued liabilities
3.3
4.83
5.66
Deferred revenue
0
0.39
9.39
Total current liabilities
7.81
9.6
15.5
Lease liabilities
8.49
5.49
1.69
Other non-current liabilities
0
0.07
0.03
Total liabilities
16.5
15.2
70.1
Paid-in capital
36.2
275
340
Retained earnings
-160
-212
-292
Shareholders' equity
-124
63.1
47.7
Total equity
-124
63.1
47.7
Total liabilities and equity
54.9
78.3
118
Shares outstanding
0.46
20.1
51.9
Cash flow statement
FY2024
FY2024
FY2025
Net income
-49.3
-51.8
-80.4
Depreciation and amortization
1.68
1.7
1.64
Stock-based compensation
2.91
4.03
4
Change in payables
-1.12
0.17
-1.03
Cash from operations
-44.2
-45.6
-29.6
Capital expenditures
-0.68
-0.44
-0.28
Cash from investing
-0.68
-0.44
-0.24
Stock issued
0
76.4
57.5
Cash from financing
0.3
71.7
75.9
Net change in cash
-44.5
25.7
46.1
Free cash flow
-44.8
-46
-29.8
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to September 30, 2026; growth uses fiscal years. Valuation uses the share price of $4.33 on November 10, 2026.
Profitability
Metric
Value
How it is calculated
Operating margin
-1,001.0%
Operating income / revenue.
EBITDA margin
-965.5%
EBITDA (operating income + depreciation and amortization) / revenue.
Net margin
-2,276.0%
Net income / revenue.
FCF margin
-496.4%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-480.1%
Cash from operations / revenue.
Return on equity (ROE)
-113.1%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-90.4%
Net income / average total assets.
R&D / revenue
757.0%
Research and development expense / revenue.
Stock-based pay / revenue
123.6%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
16.3%
Capital expenditures / revenue.
D&A / revenue
35.6%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
436.5%
Revenue vs the same period a year earlier. Only from a positive base.
Book value growth, 1y
-24.5%
Book value vs the same period a year earlier. Only from a positive base.
Total assets growth, 1y
50.4%
Total assets vs the same period a year earlier. Only from a positive base.
Share count change, 1y
547.8%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
6.42x
Current assets / current liabilities.
Quick ratio
6.27x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
6.27x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$0.07
Revenue / diluted weighted shares.
FCF per share
-$0.33
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$0.32
Cash from operations / diluted weighted shares.
Book value per share
$1.71
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
51.1x
Market cap / revenue.
P/B
2.54x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
2.54x
Market cap / tangible book value, when positive.
EV/Sales
27.7x
Enterprise value / revenue.
FCF yield
-9.7%
Free cash flow / market cap.
Earnings yield
-44.6%
Net income / market cap (the inverse of P/E).
What was Camp4 Therapeutics Corp's revenue in fiscal 2025?
Camp4 Therapeutics Corp reported revenue of $3.5M for fiscal 2025, 436.5% higher than the year before.
Was Camp4 Therapeutics Corp profitable in fiscal 2025?
No. It reported a net loss of $80.4M.
How much free cash flow did Camp4 Therapeutics Corp generate in fiscal 2025?
Cash from operations of $29.6M minus capital expenditures of $279.0K left free cash flow of -$29.8M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.